And then there were 8: Fresenius nabs the latest Humira biosimilar approval
Anticipation is building as the US prepares for an onslaught of biosimilars competing with AbbVie’s megablockbuster Humira in the coming months.
Fresenius Kabi said this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.